Navigation Links
Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
Date:9/19/2013

NEW YORK, Sept. 19, 2013 /PRNewswire/ -- Exosome Diagnostics today announced it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) for biomarker discovery and validation using Exosome Diagnostics proprietary EXO50 nucleic acid extraction kit.  Under the agreement, Lilly will gain early access to Exosome Diagnostics technology to help identify key gene mutations and expression levels in blood that may be correlated with drug response and disease recurrence.  Financial terms were not disclosed.

"Exosome Diagnostics technology may provide a unique opportunity to gain insight into the biology of complex conditions such as cancer and immune disorders," said Andrew Schade, senior medical director, diagnostic and experimental pathology at Lilly. "Exosome technology enables biofluid molecular sampling and the ability to monitor disease progression in real time. As Lilly explores new ways to pursue patient tailoring, we'll continue to work with partners to expand our capabilities." 

"Accessing high quality messenger and microRNA directly from frozen patient fluid samples offers a rapid, cost-effective route to identify and validate biomarkers, which may be correlated with drug response and disease recurrence," said James McCullough, chief executive officer of Exosome Diagnostics. "Lilly has accumulated an extensive and well annotated clinical blood sample biobank that provides a unique opportunity to track target biomarkers through the clinical trial process and help overcome the limitations of stored biopsy tissue."

Exosomes and other microvesicles are secreted by all cells into all biofluids, and provide a natural biological packaging and distribution mechanism for RNA and DNA.  Exosome Diagnostics' rapid exosome isolation and extraction technology produces high-quality RNA and DNA, including full length mRNA and microRNA, from small volumes of patient biofluids, such as blood (serum and plasma), urine and cerebrospinal fluid, for analysis by standard PCR, array and sequencing instruments. Analysis can be performed on fresh or frozen fluid samples, allowing for broad, flexible and convenient analyses of clinical trial samples, both in real-time and retrospectively, with no special preservation methods required. Exosomes and their protected nucleic acid contents are being investigated in a broad range of diseases including cancer, CNS disorders such as Alzheimer's and Parkinson's disease, cardiovascular disease, maternal/fetal medicine, and chronic kidney disease, among others. In July, QIAGEN and Exosome Diagnostics signed an agreement for the creation of High-Performance Biofluid Sample Preparation Kits for Personalized Healthcare Research which covers the exclusive supply of these products upon availability in 2014.

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. For more information, please visit www.exosomedx.com.


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
2. Aethlon Medical Announces Launch of Exosome Sciences Subsidiary
3. Aethlon Medical to Present at Exosomes and Circulating Biomarkers 2013 Summit
4. Exosome Diagnostics and QIAGEN Partner to Launch Comprehensive Line of Biofluid Nucleic Acid Kits to Address Limitations of Tissue Biopsy in Clinical Research Market
5. Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prostate Biopsy Outcome at American Urological Association Annual Meeting
6. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
7. Exosome Presents Late-Breaking Study Demonstrating Ability to Profile RNA from Archived Clinical Trial Blood Samples at 2013 American Association of Cancer Research Annual Meeting
8. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
9. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
10. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
11. Quest Diagnostics to Speak at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- Information products and services provider Elsevier ... , the world,s largest abstract and citation database of peer-reviewed literature, ... from over 5,000 publishers. The new set of metrics will improve ... when to adjust a journal,s editorial strategy. ... , , CiteScore ...
(Date:12/8/2016)... 8, 2016 According to the research ... Market is expected to be worth US$9.7 bn by ... 2015. Between the forecast years of 2016 and 2024, the ... 7.9%. The leading players operating in the global diabetes injection ... AstraZaneca plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research ...
(Date:12/8/2016)... According to a new market research report "Wearable Medical Devices Market ... Use (Sports, Fitness, RPM), Type (Smart watch, Patch), Distribution Channel (Pharmacy, Hypermarket) ... of value, is projected to reach 12.14 Billion by 2021 from USD ... period. Continue Reading ... ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in flux. The ... for the mass media launching of story movements to highlight what's most unfair ... unfortunate experiences; such a movement can generate the network power to improve healthcare ...
(Date:12/8/2016)... OH (PRWEB) , ... December 08, 2016 , ... ... insurance and financial planning services from offices headquartered in Hamilton County, is embarking ... rescue LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected ...
(Date:12/8/2016)... ... 08, 2016 , ... Coppin Insurance Agency, an insurance and financial planning firm ... Cape Coral area, is embarking on a charity drive with the goal of providing ... Harry Chapin Food Bank of Southwest Florida works to provide fresh and nutritious food ...
(Date:12/8/2016)... KS (PRWEB) , ... December 08, 2016 , ... ... financial consultation services to families and business owners in and around central Kansas, ... provide assistance to at-risk youth in the region. , Headquartered in Wichita, Youth ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... of the most comprehensive mental health systems reform legislation in more than fifty ... President, and the commitment of our elected officials to improving mental health services ...
Breaking Medicine News(10 mins):